Geoff Meacham
Stock Analyst at B of A Securities
(3.87)
# 695
Out of 4,412 analysts
150
Total ratings
54.03%
Success rate
7%
Average return
Main Sectors:
55 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $180 → $170 | $146.14 | +16.33% | 2 | Apr 17, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $710 → $720 | $883.20 | -18.48% | 4 | Apr 12, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $40 → $38 | $28.00 | +35.71% | 2 | Apr 12, 2024 | |
| BIIB Biogen | Maintains: Neutral | $280 → $260 | $208.90 | +24.46% | 9 | Apr 12, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $8 → $7 | $2.63 | +166.16% | 3 | Mar 13, 2024 | |
| JANX Janux Therapeutics | Maintains: Buy | $24 → $48 | $47.39 | +1.29% | 2 | Mar 13, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $800 → $1,000 | $733.51 | +36.33% | 7 | Mar 1, 2024 | |
| KYMR Kymera Therapeutics | Downgrades: Neutral | $45 → $30 | $33.37 | -10.10% | 3 | Jan 3, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $68 → $60 | $44.85 | +33.78% | 7 | Jan 3, 2024 | |
| IGMS IGM Biosciences | Downgrades: Neutral | $8 | $9.40 | -14.89% | 2 | Dec 15, 2023 | |
| AMGN Amgen | Reinstates: Neutral | $290 | $269.98 | +7.42% | 6 | Oct 11, 2023 | |
| NMRA Neumora Therapeutics | Initiates: Buy | $18 | $9.15 | +96.72% | 1 | Oct 10, 2023 | |
| VIR Vir Biotechnology | Downgrades: Neutral | $23 → $14 | $8.23 | +70.11% | 2 | Sep 8, 2023 | |
| GILD Gilead Sciences | Upgrades: Buy | $88 → $95 | $65.42 | +45.22% | 5 | Sep 8, 2023 | |
| CVAC CureVac | Maintains: Underperform | $10 → $8 | $2.33 | +243.35% | 4 | Aug 21, 2023 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $19 → $17 | $6.68 | +154.49% | 1 | Aug 21, 2023 | |
| TSBX Turnstone Biologics | Initiates: Buy | $18 | $2.76 | +552.17% | 1 | Aug 15, 2023 | |
| MRNA Moderna | Maintains: Neutral | $175 → $150 | $107.97 | +38.93% | 5 | Aug 4, 2023 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $200 → $185 | $80.91 | +128.65% | 1 | Jul 21, 2023 | |
| ABOS Acumen Pharmaceuticals | Reinstates: Buy | $14 | $3.17 | +341.64% | 3 | Jul 20, 2023 | |
| PFE Pfizer | Maintains: Neutral | $50 → $45 | $25.40 | +77.17% | 6 | Apr 21, 2023 | |
| AMLX Amylyx Pharmaceuticals | Initiates: Buy | $50 | $1.76 | +2,740.91% | 1 | Jan 5, 2023 | |
| MRK Merck & Co. | Upgrades: Buy | $110 → $130 | $131.20 | -0.91% | 5 | Jan 4, 2023 | |
| ABBV AbbVie | Maintains: Neutral | $162 → $165 | $159.62 | +3.37% | 11 | Dec 14, 2022 | |
| INO Inovio Pharmaceuticals | Downgrades: Underperform | $24 | $10.57 | +127.06% | 4 | Nov 1, 2022 | |
| OMER Omeros | Downgrades: Neutral | $12 → $4 | $3.15 | +26.98% | 2 | Jun 8, 2022 | |
| KNSA Kiniksa Pharmaceuticals | Maintains: Buy | $37 → $34 | $17.88 | +90.16% | 2 | Dec 29, 2021 | |
| VAXX Vaxxinity | Initiates: Buy | n/a | $0.12 | - | 1 | Dec 6, 2021 | |
| TYRA Tyra Biosciences | Initiates: Buy | n/a | $15.67 | - | 1 | Oct 11, 2021 | |
| BBIO BridgeBio Pharma | Upgrades: Buy | n/a | $24.88 | - | 2 | Sep 10, 2021 | |
| IPSC Century Therapeutics | Initiates: Buy | n/a | $2.88 | - | 1 | Jul 13, 2021 | |
| LYEL Lyell Immunopharma | Initiates: Buy | n/a | $2.17 | - | 1 | Jul 12, 2021 | |
| YMAB Y-mAbs Therapeutics | Upgrades: Buy | $56 | $14.71 | +280.69% | 3 | May 7, 2021 | |
| ESPR Esperion Therapeutics | Downgrades: Neutral | n/a | $1.90 | - | 2 | Jan 15, 2021 | |
| GLTO Galecto | Initiates: Buy | n/a | $0.70 | - | 1 | Nov 23, 2020 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | n/a | $1.75 | - | 1 | Oct 20, 2020 | |
| CRSP CRISPR Therapeutics AG | Initiates: Buy | n/a | $53.91 | - | 1 | Oct 5, 2020 | |
| MGTX MeiraGTx Holdings | Reinstates: Buy | n/a | $4.80 | - | 1 | Sep 15, 2020 | |
| SGMO Sangamo Therapeutics | Reinstates: Buy | n/a | $0.52 | - | 1 | Sep 8, 2020 | |
| PSTX Poseida Therapeutics | Initiates: Buy | n/a | $2.13 | - | 1 | Aug 4, 2020 | |
| PBYI Puma Biotechnology | Reinstates: Underperform | n/a | $5.02 | - | 1 | Jun 25, 2020 | |
| RGNX REGENXBIO | Reinstates: Buy | n/a | $16.19 | - | 1 | Jun 25, 2020 | |
| GNFT Genfit | Initiates: Underperform | n/a | $3.49 | - | 1 | Jun 25, 2020 | |
| UTHR United Therapeutics | Maintains: Underweight | n/a | $233.85 | - | 2 | Mar 1, 2019 | |
| DBVT DBV Technologies | Downgrades: Equal-Weight | n/a | $0.68 | - | 2 | Dec 20, 2018 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | n/a | $28.57 | - | 7 | Nov 6, 2018 | |
| GRTS Gritstone bio | Initiates: Overweight | n/a | $0.81 | - | 1 | Oct 23, 2018 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | n/a | $135.99 | - | 2 | Aug 1, 2018 | |
| PRTA Prothena Corporation | Downgrades: Underweight | n/a | $20.87 | - | 2 | May 21, 2018 | |
| ZYME Zymeworks | Upgrades: Equal-Weight | n/a | $8.26 | - | 2 | May 11, 2018 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | n/a | $7.82 | - | 1 | May 3, 2018 | |
| INCY Incyte | Maintains: Overweight | n/a | $51.68 | - | 2 | Apr 5, 2018 | |
| BHVN Biohaven Pharmaceutical Holding Company | Downgrades: Equal-Weight | n/a | $38.97 | - | 2 | Apr 5, 2018 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | n/a | $397.48 | - | 2 | Feb 1, 2018 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | n/a | $143.31 | - | 4 | Nov 8, 2017 |
Johnson & Johnson
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $146.14
Upside: +16.33%
Regeneron Pharmaceuticals
Apr 12, 2024
Maintains: Underperform
Price Target: $710 → $720
Current: $883.20
Upside: -18.48%
Royalty Pharma
Apr 12, 2024
Maintains: Buy
Price Target: $40 → $38
Current: $28.00
Upside: +35.71%
Biogen
Apr 12, 2024
Maintains: Neutral
Price Target: $280 → $260
Current: $208.90
Upside: +24.46%
BioXcel Therapeutics
Mar 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $2.63
Upside: +166.16%
Janux Therapeutics
Mar 13, 2024
Maintains: Buy
Price Target: $24 → $48
Current: $47.39
Upside: +1.29%
Eli Lilly
Mar 1, 2024
Maintains: Buy
Price Target: $800 → $1,000
Current: $733.51
Upside: +36.33%
Kymera Therapeutics
Jan 3, 2024
Downgrades: Neutral
Price Target: $45 → $30
Current: $33.37
Upside: -10.10%
Bristol-Myers Squibb Company
Jan 3, 2024
Downgrades: Neutral
Price Target: $68 → $60
Current: $44.85
Upside: +33.78%
IGM Biosciences
Dec 15, 2023
Downgrades: Neutral
Price Target: $8
Current: $9.40
Upside: -14.89%
Amgen
Oct 11, 2023
Reinstates: Neutral
Price Target: $290
Current: $269.98
Upside: +7.42%
Neumora Therapeutics
Oct 10, 2023
Initiates: Buy
Price Target: $18
Current: $9.15
Upside: +96.72%
Vir Biotechnology
Sep 8, 2023
Downgrades: Neutral
Price Target: $23 → $14
Current: $8.23
Upside: +70.11%
Gilead Sciences
Sep 8, 2023
Upgrades: Buy
Price Target: $88 → $95
Current: $65.42
Upside: +45.22%
CureVac
Aug 21, 2023
Maintains: Underperform
Price Target: $10 → $8
Current: $2.33
Upside: +243.35%
Rani Therapeutics Holdings
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $6.68
Upside: +154.49%
Turnstone Biologics
Aug 15, 2023
Initiates: Buy
Price Target: $18
Current: $2.76
Upside: +552.17%
Moderna
Aug 4, 2023
Maintains: Neutral
Price Target: $175 → $150
Current: $107.97
Upside: +38.93%
BioMarin Pharmaceutical
Jul 21, 2023
Maintains: Buy
Price Target: $200 → $185
Current: $80.91
Upside: +128.65%
Acumen Pharmaceuticals
Jul 20, 2023
Reinstates: Buy
Price Target: $14
Current: $3.17
Upside: +341.64%
Pfizer
Apr 21, 2023
Maintains: Neutral
Price Target: $50 → $45
Current: $25.40
Upside: +77.17%
Amylyx Pharmaceuticals
Jan 5, 2023
Initiates: Buy
Price Target: $50
Current: $1.76
Upside: +2,740.91%
Merck & Co.
Jan 4, 2023
Upgrades: Buy
Price Target: $110 → $130
Current: $131.20
Upside: -0.91%
AbbVie
Dec 14, 2022
Maintains: Neutral
Price Target: $162 → $165
Current: $159.62
Upside: +3.37%
Inovio Pharmaceuticals
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $10.57
Upside: +127.06%
Omeros
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $3.15
Upside: +26.98%
Kiniksa Pharmaceuticals
Dec 29, 2021
Maintains: Buy
Price Target: $37 → $34
Current: $17.88
Upside: +90.16%
Vaxxinity
Dec 6, 2021
Initiates: Buy
Price Target: n/a
Current: $0.12
Upside: -
Tyra Biosciences
Oct 11, 2021
Initiates: Buy
Price Target: n/a
Current: $15.67
Upside: -
BridgeBio Pharma
Sep 10, 2021
Upgrades: Buy
Price Target: n/a
Current: $24.88
Upside: -
Century Therapeutics
Jul 13, 2021
Initiates: Buy
Price Target: n/a
Current: $2.88
Upside: -
Lyell Immunopharma
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $2.17
Upside: -
Y-mAbs Therapeutics
May 7, 2021
Upgrades: Buy
Price Target: $56
Current: $14.71
Upside: +280.69%
Esperion Therapeutics
Jan 15, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.90
Upside: -
Galecto
Nov 23, 2020
Initiates: Buy
Price Target: n/a
Current: $0.70
Upside: -
PMV Pharmaceuticals
Oct 20, 2020
Initiates: Buy
Price Target: n/a
Current: $1.75
Upside: -
CRISPR Therapeutics AG
Oct 5, 2020
Initiates: Buy
Price Target: n/a
Current: $53.91
Upside: -
MeiraGTx Holdings
Sep 15, 2020
Reinstates: Buy
Price Target: n/a
Current: $4.80
Upside: -
Sangamo Therapeutics
Sep 8, 2020
Reinstates: Buy
Price Target: n/a
Current: $0.52
Upside: -
Poseida Therapeutics
Aug 4, 2020
Initiates: Buy
Price Target: n/a
Current: $2.13
Upside: -
Puma Biotechnology
Jun 25, 2020
Reinstates: Underperform
Price Target: n/a
Current: $5.02
Upside: -
REGENXBIO
Jun 25, 2020
Reinstates: Buy
Price Target: n/a
Current: $16.19
Upside: -
Genfit
Jun 25, 2020
Initiates: Underperform
Price Target: n/a
Current: $3.49
Upside: -
United Therapeutics
Mar 1, 2019
Maintains: Underweight
Price Target: n/a
Current: $233.85
Upside: -
DBV Technologies
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $0.68
Upside: -
PTC Therapeutics
Nov 6, 2018
Maintains: Equal-Weight
Price Target: n/a
Current: $28.57
Upside: -
Gritstone bio
Oct 23, 2018
Initiates: Overweight
Price Target: n/a
Current: $0.81
Upside: -
Neurocrine Biosciences
Aug 1, 2018
Maintains: Overweight
Price Target: n/a
Current: $135.99
Upside: -
Prothena Corporation
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $20.87
Upside: -
Zymeworks
May 11, 2018
Upgrades: Equal-Weight
Price Target: n/a
Current: $8.26
Upside: -
Ironwood Pharmaceuticals
May 3, 2018
Maintains: Equal-Weight
Price Target: n/a
Current: $7.82
Upside: -
Incyte
Apr 5, 2018
Maintains: Overweight
Price Target: n/a
Current: $51.68
Upside: -
Biohaven Pharmaceutical Holding Company
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $38.97
Upside: -
Vertex Pharmaceuticals
Feb 1, 2018
Maintains: Overweight
Price Target: n/a
Current: $397.48
Upside: -
Alnylam Pharmaceuticals
Nov 8, 2017
Maintains: Overweight
Price Target: n/a
Current: $143.31
Upside: -